| Name |
Delivery Strategy |
Company |
Clinical Stage |
Disease Condition Used / Treated |
| Abraxane |
protein-bound particle |
Abraxis Bioscience
[now Celgene] |
a approved |
metastatic breast cancer / NSCLC |
| NK 105 |
Polymeric micelle |
NanoCarrier |
phase III |
metastatic breast cancer / stomach cancer |
| CT-2103 |
Polymeric conjugate |
Cell Therapeutics |
phase III |
ovarian cancer |
| Genexol-PM |
Polymeric micelle |
Samyang |
phase III |
metastatic breast cancer |
| Tocosol |
emulsion |
Sonus Pharmaceuticals |
phase III / discontinued |
metastatic breast cancer |
| ANG 1005 |
peptide-bound conjugate |
Angiochem |
phase II |
glioma |
| EndoTag |
cationic liposome |
MediGene |
phase II |
metastatic breast cancer / pancreatic cancer |
| Paxceed |
Polymeric micelle |
Angiotech Pharmaceuticals |
phase II |
psoriasis |
| LEP-ETU |
liposome |
NeoPharm |
phase II |
metastatic breast cancer |
| OncoGel |
gel |
Protherics |
phase II |
esophageal cancer / primary brain cancer |
| PNU166945 |
Polymeric conjugate |
Pfizer |
phase I / discontinued |
― |
